
    
      This is first-in-human (FIH) Phase 1, open-label, multicenter, dose escalation study with
      dose expansion to evaluate the safety, tolerability, and preliminary antitumor activity of
      JNJ-67571244 in adult participants with relapsed or refractory acute myeloid leukemia (AML)
      or high-risk or very high-risk myelodysplastic syndromes (MDS) who are ineligible for or have
      exhausted standard therapeutic options. The study is divided into 3 periods: a Screening
      Phase (within 28 days before the first dose of study drug), a Treatment Phase (first dose of
      study drug until the last dose of study drug) and a Post-treatment Follow-up Phase (up to the
      end of study participation or end of study). Duration of study is 2.3 years.
    
  